Navigation Links
Tissue Culture Biologicals, Inc. Hires James D. Titus to Lead New Expansion and Branding Development Effort
Date:3/5/2013

LOS ANGELES, March 5, 2013 /PRNewswire/ -- Tissue Culture Biologicals, Inc., (TCB) has officially moved their sales office to Long Beach, California and has hired James D. Titus as their new Vice President of Sales to expand the company sales, but also to take part in getting the company well known in the industry, by branding the name.

"We are so pleased to have an executive of James's caliber join our team, and look forward to many stellar contributions as he forwards this new expansion and branding development function for us," added Lloyd Cranford , Tissue Culture Biologicals' founder and chief executive.

With over 34 years of manufacturing experience, Tissue Culture Biologicals production and distribution facility is located in the San Joaquin Valley, the heart of California's dairy industry which is critical for insuring prompt processing of locally collected blood products. TCB is licensed and inspected by the Food and Drug Administration (FDA) and the United States Department of Agriculture (USDA). Human products are handled under permits and safety regulations set forth by the Center for Disease Control (CDC).  Processing is done under strict current Good Manufacturing Practices (cGMP) guidelines established by the FDA. "In house" testing is done along with the utilization of several outside cGMP qualified laboratories to assure consistent quality control with Certificates of Analysis and Certificates of Origin provided with each order as standard procedure.

James D. Titus , VP Sales says, "Fetal Bovine Serum (FBS) has always been our primary product. However, over the years our product list has grown to include many hard to find items such as: Stem Cell Tested FBS, Female FBS, LowIG FBS, Dialyzed FBS, Delipidized FBS and Charcoal Dextran Treated FBS just to name a few. I'm excited to join a company with over 34 years of manufacturing experience, help expand the company and brand the name."

James adds, "Consumers that buy FBS serum products from Tissue Culture Biologicals can achieve significant quality, consistency and cost benefits because TCB can provide:

  • FBS serum manufactured to desired specifications
  • Large lot sizes
  • Low endotoxin lots
  • Strong lot matching capabilities
  • Low hemoglobin lots
  • Lot reservations and free storage
  • Capability and experience shipping internationally and is the only company that is approved to sell FBS serum to Europe.

"Tissue Culture Biologicals is a quarantine facility for the United States Department of Agriculture (USDA), Animal and Plant Health Inspection Service (APHIS), Veterinary Services (VS), and the National Center for Imports and Exports (NCIE). We hold USDA, APHIS, and VS permits for the importation, exportation and transportation of controlled materials, organisms and vectors. This allows us to ship and receive internationally."

To receive free samples of TCB products, go to http://www.tcbio.com/freesample.php for immediate access at zero cost.

For media inquiries, to arrange for an interview or an expert quote please contact Lloyd Cranford at 800-845-1445

Tissue Culture Biologocals, Inc. is a direct manufacturer of all types of specialized animal and human serum, located in Tulare, California. Previously manufacturing to well known and respected media and serum companies, TCB also offers high quality FBS directly to the end user under our "green" label. TCB manufactures all of its products in the U.S., allowing us to maintain the highest quality control from collection to processing to packaging. Tissue Culture Biologicals, Inc., www.tcbio.com has been manufacturing and supplying fetal bovine serum (FBS) for distributors, laboratory research operations, university lab departments, biotech research labs, vaccine labs, pharmaceutical companies and hospital research departments since 1978.

 


'/>"/>
SOURCE Tissue Culture Biologocals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New method for producing precursor of neurons, bone and other important tissues from stem cells
2. BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research
3. U.S. Tissue Engineering Markets
4. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
5. IntelliCell BioSciences Announces Collaborative Agreement with the University of Florida on Stem Cell and Tissue Repair Research
6. Beike Earns AABB Accreditation for Cord Blood and Cord Tissue Banking
7. AllCells Introduces Autoimmune Diseased Cells and Tissue Products
8. Will new methods that increase blood flow to bone implants improve viability of engineered bone tissue?
9. Precisely engineering 3-D brain tissues
10. The Alliance for Regenerative Medicine forms Tissue Engineering and Biomaterials Committee
11. Krishagni Enables University of New South Wales (Australia) to Adopt caTissue Plus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... 30, 2016 The global Pyrogen ... hold a dominant share in the overall market. The ... Inc., and Merck KGaA, held a lion,s share of ... Research observes that these companies are expected to retain ... that are do not require rabbit pyrogen testing along ...
(Date:11/30/2016)... 2016  Tempus, a technology company focused on ... Abramson Cancer Center have partnered to better determine ... immunotherapy treatment based on next generation genomic and ... a research collaboration, Tempus will provide sequencing and ... data to Penn. Utilizing next-generation sequencing, machine learning ...
(Date:11/30/2016)... ... November 30, 2016 , ... SSCI, the established leader in small-molecule ... of the latest FDA guidance on pharmaceutical cocrystals as drug substance . ... , The event follows the successful November 15th event that took place ...
(Date:11/30/2016)... Toronto, ON (PRWEB) , ... November 30, 2016 ... ... focused on discovery and development of precision treatments for neurodegenerative diseases, today announced ... disease (AD) (announced on November 3, 2016) blocked propagation of toxic, prion-like forms ...
Breaking Biology Technology:
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
Breaking Biology News(10 mins):